A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris
Public ClinicalTrials.gov record NCT07469228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study, Comparing Tretinoin Gel Microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (Tretinoin) Gel Microsphere, 0.04% (Reference Listed Drug) in the Treatment of Acne Vulgaris.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To demonstrate the efficacy, therapeutic equivalence and safety of tretinoin gel microsphere, 0.04% (Sun Pharmaceutical Industries, Inc.) and RETIN-A MICRO ® (tretinoin) gel microsphere, 0.04% (Reference Listed Drug) in the treatment of acne vulgaris.
Study identification
- NCT ID
- NCT07469228
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 1,043 participants
Conditions and interventions
Conditions
Interventions
- Tretinoin Gel Microsphere, 0.04% Drug
- RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.04% Drug
- Placebo Control Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 40 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2025
- Primary completion
- Dec 14, 2025
- Completion
- Dec 14, 2025
- Last update posted
- Mar 12, 2026
2025
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sun Pharmaceutical Industries, Inc. | Hawthorne | New York | 10532 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Acne Vulgaris trials
Other public records listing Acne Vulgaris. Sorted by last update posted; newest first. Not a recommendation.
- NCT07524946: Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo Recruiting
- NCT06225570: Weekly Isotretinoin vs Tetracycline for Moderate Acne Recruiting
- NCT05891795: Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy Active, not recruiting
- NCT07544251: Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne. Recruiting
- NCT02713607: Lipidome and Microbiome Profile of Acne Active, not recruiting
- NCT06425900: A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07469228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2026 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07469228 live on ClinicalTrials.gov.